AlphaFold predicted structure
NOG · Q13253

Mean pLDDT
86.1/ 100
Confident
232 residues
Confidence breakdown
- Very high(≥ 90)66%
- Confident(70–90)19%
- Low(50–70)10%
- Very low(< 50)5%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
noggin
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
DDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownFetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownLimb disorders
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedSkeletal dysplasia
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedPrimary ovarian insufficiency
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownRare syndromic craniosynostosis or isolated multisuture synostosis
VACTERL-like phenotypes
proximal symphalangism 1A
brachydactyly type B2
multiple synostoses syndrome 1
tarsal-carpal coalition syndrome
stapes ankylosis with broad thumbs and toes
multiple synostoses syndrome
proximal symphalangism
hereditary disease
NOG-related symphalangism spectrum disorder
Progressive visual loss
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Noggin
Inhibitor of bone morphogenetic proteins (BMP) signaling which is required for growth and patterning of the neural tube and somite. Essential for cartilage morphogenesis and joint formation. Inhibits chondrocyte differentiation through its interaction with GDF5 and, probably, GDF6 (PubMed:21976273, PubMed:26643732)
NOG · Q13253

Mean pLDDT
86.1/ 100
Confident
232 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0